301 related articles for article (PubMed ID: 34271309)
1. Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy.
Delombaerde D; Vervloet D; Franssen C; Croes L; Gremonprez F; Prenen H; Peeters M; Vulsteke C
ESMO Open; 2021 Aug; 6(4):100216. PubMed ID: 34271309
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
[TBL] [Abstract][Full Text] [Related]
6. Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy.
Tamura Y; Tamura Y; Yamada K; Taniguchi H; Iwasawa J; Yada H; Kawamura A
Heart Vessels; 2022 Nov; 37(11):1859-1865. PubMed ID: 35633369
[TBL] [Abstract][Full Text] [Related]
7. How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy.
Spallarossa P; Sarocchi M; Tini G; Arboscello E; Toma M; Ameri P; Porto I
Front Pharmacol; 2020; 11():972. PubMed ID: 32676031
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
Achim A; Liblik K; Gevaert S
Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modelling of autoimmune myocarditis and the effects of immune checkpoint inhibitors.
van der Vegt SA; Polonchuk L; Wang K; Waters SL; Baker RE
J Theor Biol; 2022 Mar; 537():111002. PubMed ID: 35007511
[TBL] [Abstract][Full Text] [Related]
11. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
[TBL] [Abstract][Full Text] [Related]
13. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
14. THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY.
Ivanovic M; Chan A; Cheng E; Xu S; Lee C; You J; Franquiz M; Fazal M; Batchelder R; Wu SM; Reddy SA; Katsumoto T; Ramchandran K; Colevas AD; Khan SA; Fan AC; Cheng P; Wakelee H; Witteles R; Neal JW; Waliany S; Zhu H
medRxiv; 2024 Jan; ():. PubMed ID: 38343840
[TBL] [Abstract][Full Text] [Related]
15. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of immune checkpoint inhibitor-related myocarditis: Retrospective experience of a single institution.
Qin Y; Zhang T; Du Z; Chen S; Li Y; Lv Y; Du X; Hu Y; Liu Z
Int Immunopharmacol; 2024 Jul; 136():112385. PubMed ID: 38850788
[TBL] [Abstract][Full Text] [Related]
17. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
[TBL] [Abstract][Full Text] [Related]
19. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
20. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
